Healthcare reality of the treatment of the high-risk multiple myeloma in Spain

被引：2
|
作者：
Hernandez-Rivas, Jose-Angel [1 ,2 ]
Gironella Mesa, Mercedes [3 ,4 ]
机构：
[1] Hosp Univ Infanta Leonor, Serv Hematol & Hemoterapia, Madrid, Spain
[2] Univ Complutense Madrid, Dept Med, Madrid, Spain
[3] Hosp Univ Vail dHebron, Serv Hematol, Barcelona, Spain
[4] Univ Autonoma Barcelona, Dept Med, Barcelona, Spain
来源：
MEDICINA CLINICA | 2020年 / 154卷 / 08期
关键词：
LENALIDOMIDE PLUS DEXAMETHASONE; TREATMENT STRATEGIES; CONSENSUS; STRATIFICATION; CARFILZOMIB; GUIDELINES; MANAGEMENT; SURVIVAL;
D O I：
10.1016/j.medcli.2019.10.006
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：315 / 319
页数：5
相关论文
共 50 条
  • [1] Frontline Treatment for High-Risk Multiple Myeloma: Personalized?
    Usmani, Saad
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S89 - S89
  • [2] Treatment options for multiple myeloma patients with high-risk disease
    Ailawadhi, Sikander
    Masood, Aisha
    Sher, Taimur
    Miller, Kena C.
    Wood, Margaret
    Lee, Kelvin
    Chanan-Khan, Asher
    MEDICAL ONCOLOGY, 2010, 27 : 53 - 61
  • [3] Treatment options for multiple myeloma patients with high-risk disease
    Sikander Ailawadhi
    Aisha Masood
    Taimur Sher
    Kena C. Miller
    Margaret Wood
    Kelvin Lee
    Asher Chanan-Khan
    Medical Oncology, 2010, 27 : 53 - 61
  • [4] Multiple myeloma with high-risk cytogenetics and its treatment approach
    Ichiro Hanamura
    International Journal of Hematology, 2022, 115 : 762 - 777
  • [5] Nivolumab for Treatment of Advanced, Refractory, High-Risk Multiple Myeloma
    Thanendrarajan, Sharmilan
    Puryear, Jerry
    Schinke, Carolina D.
    van Rhee, Frits
    Zangari, Maurizio
    Mathur, Pankaj
    Mohan, Meera
    Susanibar, Sandra
    Kamimoto, Jorge Jo
    Hoque, Shadiqul
    Radhakrishnan, Muthukumar
    Farmer, Phil
    Rasche, Leo
    Weinhold, Niels
    Walker, Brian A.
    Davies, Faith E.
    Morgan, Gareth J.
    BLOOD, 2017, 130
  • [6] Multiple myeloma with high-risk cytogenetics and its treatment approach
    Hanamura, Ichiro
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2022, 115 (06) : 762 - 777
  • [7] Approach to High-Risk Multiple Myeloma
    Chen, Xiaoyi
    Varma, Gaurav
    Davies, Faith
    Morgan, Gareth
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2024, 38 (02) : 497 - 510
  • [8] Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group
    Sonneveld, Pieter
    Avet-Loiseau, Herve
    Lonial, Sagar
    Usmani, Saad
    Siegel, David
    Anderson, Kenneth C.
    Chng, Wee-Joo
    Moreau, Philippe
    Attal, Michel
    Kyle, Robert A.
    Caers, Jo
    Hillengass, Jens
    San Miguel, Jesus
    van de Donk, Niels W. C. J.
    Einsele, Hermann
    Blade, Joan
    Durie, Brian G. M.
    Goldschmidt, Hartmut
    Mateos, Maria-Victoria
    Palumbo, Antonio
    Orlowski, Robert
    BLOOD, 2016, 127 (24) : 2955 - 2962
  • [9] TREATMENT OF HIGH-RISK TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA PATIENTS
    Patriarca, F.
    HAEMATOLOGICA, 2021, 106 (10) : 209 - 211
  • [10] Treatment of high-risk smoldering myeloma
    Korde, Neha
    SEMINARS IN ONCOLOGY, 2016, 43 (06) : 695 - 696
12345